264 related articles for article (PubMed ID: 31754644)
1. Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers.
Sinkala M; Mulder N; Patrick Martin D
Commun Biol; 2019; 2():414. PubMed ID: 31754644
[TBL] [Abstract][Full Text] [Related]
2. Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia.
Haider S; McIntyre A; van Stiphout RG; Winchester LM; Wigfield S; Harris AL; Buffa FM
Genome Biol; 2016 Jun; 17(1):140. PubMed ID: 27358048
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA Regulation of Energy Metabolism to Induce Chemoresistance in Cancers.
Ye J; Zou M; Li P; Liu H
Technol Cancer Res Treat; 2018 Jan; 17():1533033818805997. PubMed ID: 30444190
[TBL] [Abstract][Full Text] [Related]
4. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
5. High ELF4 expression in human cancers is associated with worse disease outcomes and increased resistance to anticancer drugs.
Kafita D; Daka V; Nkhoma P; Zulu M; Zulu E; Tembo R; Ngwira Z; Mwaba F; Sinkala M; Munsaka S
PLoS One; 2021; 16(4):e0248984. PubMed ID: 33836003
[TBL] [Abstract][Full Text] [Related]
6. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
7. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
8. Alterations of metabolic genes and metabolites in cancer.
Oermann EK; Wu J; Guan KL; Xiong Y
Semin Cell Dev Biol; 2012 Jun; 23(4):370-80. PubMed ID: 22306135
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations.
Choi H; Na KJ
Mol Cancer; 2018 Oct; 17(1):150. PubMed ID: 30333042
[TBL] [Abstract][Full Text] [Related]
10. How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
Icard P; Shulman S; Farhat D; Steyaert JM; Alifano M; Lincet H
Drug Resist Updat; 2018 May; 38():1-11. PubMed ID: 29857814
[TBL] [Abstract][Full Text] [Related]
11. Integration of transcriptomic data and metabolic networks in cancer samples reveals highly significant prognostic power.
Graudenzi A; Maspero D; Di Filippo M; Gnugnoli M; Isella C; Mauri G; Medico E; Antoniotti M; Damiani C
J Biomed Inform; 2018 Nov; 87():37-49. PubMed ID: 30244122
[TBL] [Abstract][Full Text] [Related]
12. Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source.
Foster R; Griffin S; Grooby S; Feltell R; Christopherson C; Chang M; Sninsky J; Kwok S; Torrance C
PLoS One; 2012; 7(9):e45061. PubMed ID: 23028762
[TBL] [Abstract][Full Text] [Related]
13. Systematic analysis of genotype-specific drug responses in cancer.
Kim N; He N; Kim C; Zhang F; Lu Y; Yu Q; Stemke-Hale K; Greshock J; Wooster R; Yoon S; Mills GB
Int J Cancer; 2012 Nov; 131(10):2456-64. PubMed ID: 22422301
[TBL] [Abstract][Full Text] [Related]
14. Metabolic heterogeneity signature of primary treatment-naïve prostate cancer.
Lin D; Ettinger SL; Qu S; Xue H; Nabavi N; Choi SYC; Bell RH; Mo F; Haegert AM; Gout PW; Fleshner N; Gleave ME; Pollak M; Collins CC; Wang Y
Oncotarget; 2017 Apr; 8(16):25928-25941. PubMed ID: 28460430
[TBL] [Abstract][Full Text] [Related]
15. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.
Chang WH; Lai AG
BMC Cancer; 2020 Aug; 20(1):773. PubMed ID: 32807122
[TBL] [Abstract][Full Text] [Related]
16. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract][Full Text] [Related]
17. Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers.
Yu TJ; Ma D; Liu YY; Xiao Y; Gong Y; Jiang YZ; Shao ZM; Hu X; Di GH
Mol Ther; 2021 Jul; 29(7):2350-2365. PubMed ID: 33677091
[TBL] [Abstract][Full Text] [Related]
18. Profiling of the metabolic transcriptome via single molecule molecular inversion probes.
de Bitter T; van de Water C; van den Heuvel C; Zeelen C; Eijkelenboom A; Tops B; Oosterwijk E; Kolev D; Mulders P; Ter Laan M; van Lith S; Leenders W
Sci Rep; 2017 Sep; 7(1):11402. PubMed ID: 28900252
[TBL] [Abstract][Full Text] [Related]
19. Explainable drug sensitivity prediction through cancer pathway enrichment.
Tang YC; Gottlieb A
Sci Rep; 2021 Feb; 11(1):3128. PubMed ID: 33542382
[TBL] [Abstract][Full Text] [Related]
20. Gene Expression Integration into Pathway Modules Reveals a Pan-Cancer Metabolic Landscape.
Cubuk C; Hidalgo MR; Amadoz A; Pujana MA; Mateo F; Herranz C; Carbonell-Caballero J; Dopazo J
Cancer Res; 2018 Nov; 78(21):6059-6072. PubMed ID: 30135189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
